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715daysafterpotentialproblemsrelatedtoPTUuseinchildrenwerepresentedinadebateinfrontoftheLawsonWilkinsPediatric
Endocrine Society (LWPES), the US Food and Drug Administration issued a “black-box” warning about the hepatotoxicity risk
of the antithyroid drug propylthiouracil (PTU). This safety advisory followed the collective actions of academic societies, medical
publishers, the National Institutes of Health, and the FDA. Considering that surgery and radioactive iodine are the legitimate
treatment options for Grave Disease (GD), and are now the preferred alternative therapy in individuals who developed toxic
reactions to MMI, the use of PTU should now be limited to exceptional circumstances and pregnancy. Long-term PTU therapy,
especially in children, is not justiﬁable. The current advisory comes 63 years after the introduction of PTU for clinical use in 1947.
715 days after potential problems related to PTU use in
children were presented in a debate in front of the Lawson
Wilkins Pediatric Endocrine Society (LWPES), the US Food
and Drug Administration issued a black-box warning about
the hepatotoxicity risk of the antithyroid drug propylth-
iouracil (PTU) [1].
This safety advisory stated that “The United States
Food and Drug Administration (FDA) has added a Boxed
Warning to the label for propylthiouracil, a drug used
to treat hyperthyroidism (overactive thyroid), to include
information about reports of severe liver injury and acute
liver failure, some of which have been fatal, in adult and
pediatric patients using this medication.” [1]. This safety
advisoryfollowedthecollectiveactionsofacademicsocieties,
medical publishers, the National Institutes of Health, and
the FDA, all with the same goal—ending PTU-induced
liver failure. This safety advisory comes 63 years after the
introduction of PTU for clinical use for the treatment of
hyperthyroidism in 1947.
Three years ago, a perspective advocating surgery as
the primary form of deﬁnitive therapy for children with
Graves’ disease (GD) was published in The Journal of
Clinical Endocrinology and Metabolism (JCEM) along with a
counterpointcommentaryontheuseofradioactiveiodinein
GD[2,3].TheprintdiscoursecaughttheattentionofLWPES
program planners.
On May 4, 2008, at the annual meeting of LWPES, a
“Great Debate” was held between Dr. Melvin Grumbach
of the University of California, San Francisco and Dr.
Scott Rivkees of Yale University, focusing on the merits of
surgery versus radioactive iodine treatment. Beforehand, the
discussants agreed to comment on the risks associated with
antithyroid drugs. A slide was presented stating that “Anti-
thyroid Medication use Should not be Viewed as Trivial in
Children. We need a black-box warning”.
After the presentation and after the meeting, one of the
discussants was made aware of what seemed to be a cluster
of complications related to PTU. Girls aged 6, 8, and 14 years
were described to have develop liver failure leading to liver
transplantation within the previous two years. A 10-year-old
girl who died of complications related to PTU more than a
decade ago was brought to attention.
Following the meeting, PubMed.com searching revealed
more than 40 reports of PTU-related liver failure and 10
reports of PTU-related deaths. There were ﬁve reports of
PTU-related liver transplants. Of concern, 30% of cases were
children. There were no reports of methimazole- (MMI-
)related liver failure in the pediatric population and far fewer
reports of other serious adverse events for MMI than PTU.
(These observations are summarized in the minutes of the
BPCA hearing of October 28, 2009; see [4].)2 International Journal of Pediatric Endocrinology
These concerning ﬁndings were brought to the attention
of the FDA Division of Pharmacovigilance. These ﬁndings
were also discussed on a Society Network of Pediatric
Endocrinology (SNoPE) conference call, involving Dr. Karen
Winer of the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD). The
PTU-related adverse event data were forward to Dr. Winer
and Dr. Donald Mattison, Branch Chief, Obstetric and
Pediatric Pharmacology Branch (OPPB), and Director of
the Best Pharmaceuticals for Children Act (BPCA). Upon
review of the data, Dr. Mattison relayed concerns about a
possible safely alert signal for PTU to the FDA. FDA database
interrogation validated a potential safety problem.
Three weeks later, on October 28, 2008, a special
workshop was held at NICHD under sponsorship of the
OPPB and BPCA [4]. Meeting participants included experts
in thyroidology, pediatric endocrinology, hepatology, drug
epidemiology, and members of the FDA and NIH. To
identify the potential number of children at risk, pharmaco-
epidemiology studies were performed. It was estimated that
more than 2,500 children were taking PTU at the time of
the hearings. (A more detailed analysis of PTU use has been
recently reported [5].) FDA Adverse Event Reporting System
(AERS) data revealed three pediatric deaths and 20 cases
of acute severe liver injury in children of the previous 20
years. (A more detailed analysis of hepatotoxicity has been
recently reported [6].) Data from the United Network of
Organ Sharing (UNOS) revealed 10 liver transplants related
to PTU over the proceeding 14 years, and no evidence for
liver failure associated with MMI over this time. Of note,
several cases of liver failure in the UNOS database were not
in the FDA AERS database.
It was estimated that one child per year in the US
developed PTU-induced liver failure leading transplantation
or death. The risk of PTU-induced liver failure leading
to transplantation was estimated to be about 1 in 2000
children. The number of children developing PTU-induced
liver injury that was reversible was estimated to be about 1
in 200. In comparison, there was no risk of liver failure with
MMI. Importantly, routine biochemical surveillance of liver
transaminase levels and liver function was not expected to
be useful in identifying children who would develop PTU-
inducedliverfailure.Thus,theonlyeﬀectivewaytominimize
hepatotoxicity risk is to avoid PTU use.
Because of the nature of the workshop, formal speciﬁc
recommendations were not made by the group. Drs. Rivkees
and Mattison, though, developed pediatric-speciﬁc recom-
mendations based on the following data.
(i) PTU should never be used as a ﬁrst line treatment in
children.
(ii) PTU should only be used in rare circumstances such
aspreparationforsurgeryinapatientallergictoMMI
and use should be short-term.
(iii) PTU use in the children on therapy should be
immediately stopped in favor of alternative therapies.
On April 9, 2009, Drs. Rivkees and Mattison published a
letterinTheN ewE nglandJ ournalofM edicine(NEJM)calling
attention to the BPCA hearings and detailing recommenda-
tions for discontinuation of PTU use [7]. A complementary,
extensive report of the issue was simultaneously published in
the International Journal of Pediatric Endocrinology [8].
Soonafterpublicationofthe NEJM letter,TheEndocrine
Society (TES) convened a panel of experts to address
this issue. On April 15, 2009, TES issued a statement
recommending that PTU not be used in children [9]. Two
weeks later, the LWPES sent an alert to the members calling
attention to the NEJM letter.
Recognizing that PTU-related liver toxicity was not
unique to pediatric patients, a hearing was organized focus-
ing on PTU risks in adults that was held on April 18, 2009,
in Washington DC [10]. This hearing was jointly sponsored
by the FDA and the American Thyroid Association (ATA).
ATA representation included the Hyperthyroidism Task
Force, chaired by Dr. Rebecca Bahn, of the Mayo Clinic.
Considering that PTU is the antithyroid drug of choice
during pregnancy, antithyroid drug use during pregnancy
was a focus of the hearings.
The risk of PTU-induced liver failure leading to trans-
plantation was estimated to be about 1 in 10,000 adults. The
number of adults developing PTU-induced liver injury that
was reversible was estimated to be about 1 in 100 individuals.
The risk and nature of liver injury associated with MMI
was estimated to be much less than that with PTU. Concern
was raised that MMI may have potential teratogenic eﬀects
(aplasia cutis, choanal atresia, esophageal atresia, and other
malformations);however,itwasnotclearifMMIbirthdefect
risks were above background rates.
Based on the data presented, to minimize the risks of
PTU to the mother and minimize the risk of MMI birth
defects, the ATA Hyperthyroidism Task Force suggested that
PTU use be restricted to the ﬁrst trimester and MMI be used
over the remainder of pregnancy. The need for additional
research to deﬁne the relative risks of PTU and MMI during
pregnancy was noted. A premium was placed on deﬁnitive
therapy for women of childbearing years with GD, to avoid
the need for antithyroid drugs during pregnancy.
Just after the April 18, 2009 meeting Drs. Cooper and
Rivkees published a perspective on the risks of PTU in
children and adults in JCEM at the request of the Editor-in-
Chief further detailing PTU hepatotoxicity risks along with
use recommendations [11]. Other reports were prepared
for the American Association of Clinical Endocrinology
[12] and the American Academy of Pediatrics [13]. The
recommendations of the ATA Hyperthyroidism Task Force
focusing on pregnancy were published in Thyroid af e w
months later [14].
Despite the publicity of associated with the NEJM letter
andTESrecommendationsthatPTUnotbeusedinchildren,
in early May 2009, an 11-year-old girl was transferred to
the Yale Pediatric Thyroid Center and Yale-New Haven
Children’s Hospital with impending liver failure. Acute liver
injury developed 6 weeks into PTU therapy for GD; the
liver injury reversed and the girl was treated with radioactive
iodine.ThecircumstancesofthecasewererelayedtotheFDA
Division of Metabolism and Endocrinology Products and to
the LWPES on May 13, 2009.International Journal of Pediatric Endocrinology 3
On May 13, 2009 the LWPES issued an email alert to
all members encouraging practitioners to avoid PTU use in
children.OnJune4,2009,theFDAissuedawidelypublicized
safety alert, notifying healthcare professionals of “serious
risks,including liverfailureanddeathassociatedwiththeuse
of PTU in adult and pediatric patients” [15]. This alert was
designated the #1 Endocrine Alert of 2009 by MedWatch.
In early June 2009, we became aware of another child
in the US who developed liver failure a few months into
PTU therapy; this child underwent a liver transplant. We are
unaware of subsequent cases.
About one month after the April 18th meeting, the
ATA was requested by the FDA to consider modiﬁcation
of product labeling of PTU. The ATA Hyperthyroidism
Task Force submitted recommendations to the FDA in
June 2009. Continuing to issue warnings, the FDA issued
another PTU safety alert and posted an online informational
show in August 2009 [16]. The program stated “do not
use propylthiouracil in children unless they cannot take
methimazole and no other treatments available” [17].
On April 21, 2010, 63 years after the drug was introduced
for clinical use, the FDA “box warning” went into the
label for PTU [1]. The warning included information about
acute, severe, and fatal liver injury in the pediatric and
adult population using this medication. FDA warnings also
contained the recommendations that PTU should not be
used in pediatric patients unless the patient is allergic to or
intolerant of MMI and there are no other treatment options
available, matching the original recommendations of Drs.
Rivkees and Mattison [7, 8].
Considering that surgery and radioactive iodine are the
legitimate treatment options for GD and are now the pre-
ferred alternative therapy in individuals who developed toxic
reactions to MMI, the use of PTU in children (and adults)
should now be limited to exceptional circumstances and
pregnancy. Long-term PTU therapy, especially in children,
is not justiﬁable.
715daysafter“AntithyroidMedicationuseShouldnotbe
Viewed as Trivial in Children. We need a black-box warning”
was ﬂashed on a meeting screen, we now have one. Time and
outcomes of children treated for GD will tell when we can
ﬂash “Mission Accomplished.”
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